Publishing openly helps research be seen, shared, and built on.
The latest metrics for Frontiers in Immunology are here: a Journal Impact Factor of 7.0 and a CiteScore of 11.3.
Explore the community behind this journal ⬇️
#QualityChampions#Impact2026
New Research: Imbalance of type I and II onterferon pathways is associated with pain perception in Sjogren’s disease: a real-life study https://t.co/IEGsn18ldS #FrontiersIn#Immunology
Last week at the Sino-Swiss Conference, we showed how our journal protects the scientific record and why our approach stands apart. For more than a decade, we have built research integrity into how we publish so the immunology community can trust what it reads and builds on.
New Research: The therapeutic potential of compounds from natural products for alleviating depression by targeting P2X7 receptor-mediated proinflammatory signaling pathways https://t.co/R8I1zsCJTM #FrontiersIn#Immunology
One of @wef's top ten emerging technologies is 'Personalized mRNA Cancer Vaccines: turning tumour cells into personalized treatment.'
Special Chief Editor of Frontiers in Immunology, Rita Carsetti, is one of the authors of the report.
Learn more ⬇️
Image Credit: @wef
New Research: Berberine protects against hypoxia-induced intestinal injury through modulation of gut microbiota and bile acid metabolism https://t.co/mZ7y9VqOF8 #FrontiersIn#Immunology
New Research: Treatment of toxic epidermal necrolysis in a patient with extensive skin damage induced by dimethyl N-cyanodithioiminocarbonate: a case report https://t.co/etGw9qqR6M #FrontiersIn#Allergy
We’re leading the way using AI to strengthen peer review while upholding the highest standards of integrity.
With AIRA, our own AI-powered assistant, we run 40+ checks in seconds to flag potential issues before review begins, empowering researchers to focus on the science.
Every study helps build something bigger.
Your research is the real superpower behind the latest impact metrics for Frontiers in Allergy: a Journal Impact Factor of 3.4 and a CiteScore of 4.3.
Explore the community behind this impact ⬇️
New Research: Chemotherapy driven alterations in NK cell receptors and ligands in high grade serous ovarian cancer https://t.co/HTlw3ubIz4 #FrontiersIn#Immunology
New Research: Chemokine ligand-receptor interactions as potential therapeutic targets for atopic dermatitis: from basic to clinical research https://t.co/Rs2PQOlp0r #FrontiersIn#Allergy
Two industry awards. One message: trusted science needs openness, integrity and responsible innovation.
A double win for Frontiers at the 2026 EPIC Awards from the Society for Scholarly Publishing.
🥇 Gold for our AI white paper
🥈 Silver for our Guardians of Science campaign
New Research: Immunonutritional biomarkers in osteoarthritis: mechanistic insights and prognostic potential https://t.co/4fa9hLScoh #FrontiersIn#Immunology
New Research: Graduate-level medical doctors in Uganda have limited awareness of warning, specific signs, and immunological investigations of primary immunodeficiencies https://t.co/LCxRkuRLk2 #FrontiersIn#Immunology